Back to Journals » Open Access Rheumatology: Research and Reviews » Volume 12

Efficacy of Ustekinumab Against Spondyloarthritis Associated with Crohn’s Disease: A Case Report and Review of the Literature

Authors Matsumoto S, Matsumoto K, Takaya H, Otake H, Mashima H

Received 18 May 2020

Accepted for publication 14 July 2020

Published 29 July 2020 Volume 2020:12 Pages 133—137


Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Professor Chuan-Ju Liu

Satohiro Matsumoto, Keita Matsumoto, Hiromu Takaya, Haruka Otake, Hirosato Mashima

Saitama Medical Center, Jichi Medical University, Saitama, Saitama, Japan

Correspondence: Satohiro Matsumoto Email

Abstract: Spondyloarthritis (SpA) is a known extraintestinal complication in inflammatory bowel disease (IBD). However, since the prevalence of SpA is lower in Japan than in Europe, some patients may be inaccurately diagnosed and treated. Although non-steroidal anti-inflammatory drugs (NSAIDs) remain the mainstay treatment for IBD-related SpA, anti-tumor necrosis factor-α antibody and ustekinumab have demonstrated efficacy in patients with SpA refractory to NSAIDs. We report here a case of Crohn’s disease with SpA, as an extraintestinal manifestation, in which ustekinumab proved extremely effective, not only for alleviating the arthritis but also against skin manifestations and scleritis. Only a few studies have documented the therapeutic effects of ustekinumab against SpA associated with IBD; therefore, its efficacy remains unclear.

Keywords: ustekinumab, spondyloarthritis, Crohn’s disease

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]